AVCTF (Avacta Group) Institutional Ownership: 4.81% (As of Jul. 04, 2026)


AVCTF Avacta Group PLC AVCTF
13 GF Score
Price $1.00
GF Value $0.67
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Avacta Group Institutional Ownership?

Avacta Group AVCTF 13 Institutional Ownership is 4.81% as of Jul. 04, 2026. GuruFocus rates AVCTF with a GF Score™ of 13/100 and a GF Value™ of $0.67 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Avacta Group's institutional ownership is 4.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Avacta Group's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Avacta Group's Float Percentage Of Total Shares Outstanding is 0.00%.

Avacta Group Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Avacta Group's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avacta Group Institutional Ownership Chart

Avacta Group Historical Data

The historical data trend for Avacta Group can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31
Institutional Ownership 3.21 3.21 3.15 3.23 2.70 2.70 2.72 2.94 3.05 3.05
AVCTF
13GF Score
Avacta Group PLC AVCTF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avacta Group Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 4.81% mean?
Avacta Group (AVCTF) has a Institutional Ownership of 4.81% as of Jul. 04, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Avacta Group and its competitors.
Is Avacta Group's Institutional Ownership too high?
Avacta Group's current Institutional Ownership is 4.81%. Overall, Avacta Group has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Institutional Ownership compare to VRTX and REGN?
Avacta Group's Institutional Ownership of 4.81% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Avacta Group and its competitors. Avacta Group's current Institutional Ownership is 4.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $1.00 — trading 49.3% above its estimated fair value. The current Institutional Ownership is 4.81%. Avacta Group's overall GF Score™ is 13/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Avacta Group (AVCTF), the current Institutional Ownership is 4.81% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avacta Group (AVCTF) Overvalued in 2026?

Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued. The current stock price of $1.00 is trading 49.3% above its estimated GF Value™ of $0.67. GuruFocus considers Avacta Group to be Significantly Overvalued.

Key valuation signals for AVCTF:

  • Institutional Ownership: 4.81%
  • GF Value™: $0.67 vs. price of $1.00 (49.3% above fair value)
  • GF Score™: 13/100 with 8 warning signs

No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avacta Group Business Description

Other Exchanges AVCT:UKRTQ1:Germany
Address 58 Wood Lane, White City Imperial College Campus, Scale Space, London, GBR, W12 7RZ
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
13GF Score

Get the complete analysis for AVCTF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price
$0.67
GF Value